PAN2

Across TCGA pan-cancer cohorts, PAN2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PAN2 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PAN2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PAN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where PAN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	18	view →
LUAD	DFS	Tertile	II,III,IV	0.754	0.231	.025	6	view →
CCRCC	DFS	Tertile	II,III,IV	0.447	0.782	.017	5	view →
HNSC	OS	Median	All	0.777	0.911	.007	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PAN2–PDAC (DFS)

Open the PDAC breakdown →